ArticleAntibiotics (Basel, Switzerland)2022
Assessment of In-Vitro Synergy of Fosfomycin with Meropenem, Amikacin and Tigecycline in Whole Genome Sequenced Extended and Pan Drug Resistant
Article in Antibiotics (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 20 citations in OpenAlex.
- The Evolving Clonal, Plasmid-Mediated Resistome, Virulome and Therapeutic Landscape of Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2026Article
- Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2026Article
- Article
- Article
- Mapping Antimicrobial Resistance inDiagnostics (Basel, Switzerland) · 2025Article
- Assessment of Phenotypic Tools for Detection of OXA-48, KPC, and NDM inDiagnostics (Basel, Switzerland) · 2025Article
- Overcoming the drug resistance barrier: progress in fosfomycin combination therapy against multidrug-resistant pathogens.Frontiers in microbiology · 2025Review
- Epidemiologic analysis of antimicrobial resistance in hospital departments in China from 2022 to 2023.Journal of health, population, and nutrition · 2024Article
- Evaluation of six commercial and in-house phenotypic tests for detection of AmpC β-lactamases: is routine detection possible?JAC-antimicrobial resistance · 2023Article
- Comparative Genomic Analysis Reveals the Emergence of ST-231 and ST-395Microorganisms · 2023Article
- Exploring Synergistic Combinations in Extended and Pan-Drug Resistant (XDR and PDR) Whole Genome SequencedMicroorganisms · 2023Article
- A panel of diverseMicrobial genomics · 2023Article
- In Vitro and In Vivo Synergism of Fosfomycin in Combination with Meropenem or Polymyxin B against KPC-2-ProducingAntibiotics (Basel, Switzerland) · 2023Article
- Assessment of the Susceptibility of Clinical Gram-Negative and Gram-Positive Bacterial Strains to Fosfomycin and Significance of This Antibiotic in Infection Treatment.Pathogens (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fosfomycin has emerged as a very useful antimicrobial in management of extremely drug resistant (XDR) and pan drug resistant (PDR)
methodNon-replicate fully characterised 18 clinical isolates of
resultsFOS-MEM and FOS-AK both demonstrated excellent synergy against all PDRs and all but one XDR. Synergy led to lowering of MICs to susceptible breakpoints. FOS-TGC demonstrated antagonism. MLST-231
conclusionFOS + MEM and FOS + AK are excellent colistin sparing combinations against ST 231, ST-395 and ST-147 XDR and PDR
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.